vandetanib-eluting radiopaque beads

BTG-002814 is a novel drug delivery system consisting of vandetanib-eluting radiopaque beads designed for transarterial chemoembolization (TACE) in liver cancer patients. It contains 100 mg of vandetanib loaded onto tiny radiopaque beads. When injected into the hepatic artery, these beads lodge in blood vessels feeding the tumor, blocking blood flow and releasing vandetanib directly into the tumor microenvironment. The radiopaque nature of the beads allows physicians to visualize their distribution using CT scans, enabling more precise delivery and treatment monitoring. Vandetanib itself is a multi-targeted tyrosine kinase inhibitor that acts as a RET inhibitor, VEGFR-2 inhibitor, and EGFR antagonist. These mechanisms allow vandetanib to target both angiogenesis (blood vessel formation) and direct cancer cell growth, even in hypoxic (low-oxygen) conditions.

Other names

vandetanib-eluting radiopaque embolic beads